Axogen Announces Promotions on Research and Development Team
04 Januar 2024 - 10:35PM
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing
and marketing innovative surgical solutions for peripheral nerve
injuries, today announced the promotions of three research and
development team members. The promotions are:
- Erick DeVinney to Chief Innovation Officer Mr. DeVinney joined
Axogen in April of 2007 as Director of Clinical Research. During
his tenure, he has held positions of progressive responsibility in
Clinical Research, Research and Development, Product Development,
Medical Education, and Medical Affairs. Mr. DeVinney has more than
16 years of experience driving innovation in peripheral nerve
injury diagnosis and repair, including clinical and regulatory
development strategies, portfolio development, and scientific
thought leadership. He has a diverse background, including academic
research and the development of tissue technologies, medical
devices, pharmaceuticals, and biologics. Mr. DeVinney has been
involved in research at the Virginia Commonwealth University
Medical College of Virginia Hospitals, University of Utrecht,
National Clinical Research, PRA International, and Angiotech. He
has been involved in the successful submission of eight IDE or NDA
applications, as well as numerous 510(k)s. Mr. DeVinney also serves
as a Board Member for the Global Nerve Foundation. He has a B.S.
degree in Chemistry from Virginia Commonwealth University.
- Ivica Ducic, M.D., Ph.D., to Chief Medical Officer Dr.
Ducic joined Axogen as Medical Director in January 2017. He is a
board-certified plastic surgeon, with additional training and
expertise in peripheral nerve surgery. He received his medical
degree in 1991 from the University of Zagreb School of Medicine
(Croatia, Europe), and a Ph.D. degree in 1995 in neuroscience. Upon
completing plastic surgery training at Georgetown University
Hospital in 2002, he entered a one-year peripheral nerve surgery
fellowship. He then joined the full-time faculty practice at
Georgetown University Hospital Department of Plastic Surgery in
August 2003, where he served as a professor of plastic surgery and
neurosurgery. In 2014, Dr. Ducic established his own practice, the
Washington Nerve Institute in McLean, Virginia. Among his many
accomplishments, Dr. Ducic is the Past-President of the American
Society for Peripheral Nerve, has served on many committees,
published more than 100 peer-reviewed papers, authored 17 book
chapters, and has been a prolific invited educator both nationally
and internationally on the diagnosis and treatment of peripheral
nerve injury. During his past seven years at Axogen, Dr. Ducic has
been an instrumental leader in the development of new technologies,
applicable surgical techniques, surgeon education, as well as
providing strategic guidance for the core company mission –
improving the quality of life of patients with nerve injuries.
- Stacy Arnold to Vice President of Product Development and
Clinical Research Ms. Arnold has served as Vice
President of Clinical Research for Axogen since June 2019. She
initially joined Axogen in April 2018 as Vice President of Program
Management. She has been leading the research, development, and
execution of clinical strategies to strengthen and advance the body
of evidence for new technologies and clinical applications to
restore nerve function and quality of life to patients with
peripheral nerve injuries. Ms. Arnold previously served as Senior
Director of R&D and Program Management at Artivion (formerly
CryoLife), driving global innovation and new product development of
medical devices, biologics, and tissue technologies, while leading
successful program management processes and business strategies to
drive growth and deliver shareholder value. Ms. Arnold serves as a
Board Member on Mercer University’s National Engineering Advisory
Board. She has an M.S. in Engineering from the University of Toledo
and a B.S. in Biomedical Engineering from Mercer University. She
also holds a global Project Management Professional Certification
from the Project Management Institute.
In addition, the Company is announcing the departure of Angelo
Scopelianos, Ph.D., Axogen’s Chief Research and Development
Officer, in the first quarter of 2024.
“We want to thank Angelo for his contributions in new programs
that led to innovations like the launch of Axoguard HA+ Nerve
ProtectorTM and the upcoming launch of Avive+ Soft Tissue MatrixTM
and we are pleased to announce the internal promotions of these
leaders in our research and development team,” said Karen Zaderej,
Axogen’s Chairman, CEO and President. “This is a strong, highly
accomplished group that has worked together closely for many years
and demonstrated great success in supporting our mission of
improving the lives of patients with peripheral nerve injuries. The
continuity of this expert team will also be important to Axogen as
we move through the BLA submission process of Avance® Nerve Graft
toward the next commercial phase of our business as a biologic.
About Axogen
Axogen (AXGN) is the leading Company focused
specifically on the science, development, and commercialization of
technologies for peripheral nerve regeneration and repair. Axogen
employees are passionate about helping to restore peripheral nerve
function and quality of life to patients with physical damage or
transection to peripheral nerves by providing innovative,
clinically proven, and economically effective repair solutions for
surgeons and health care providers. Peripheral nerves provide the
pathways for both motor and sensory signals throughout the body.
Every day, people suffer traumatic injuries or undergo surgical
procedures that impact the function of their peripheral nerves.
Physical damage to a peripheral nerve, or the inability to properly
reconnect peripheral nerves, can result in the loss of muscle or
organ function, the loss of sensory feeling, or the initiation of
pain.
Axogen's platform for peripheral nerve repair
features a comprehensive portfolio of products that are used across
two primary application categories: scheduled, non-trauma
procedures and emergent trauma procedures. Scheduled procedures are
generally characterized as those where a patient is seeking relief
from conditions caused by a nerve defect or surgical procedure.
These procedures include providing sensation for women seeking
breast reconstruction following a mastectomy, nerve reconstruction
following the surgical removal of painful neuromas, oral and
maxillofacial procedures, and nerve decompression. Emergent
procedures are generally characterized as procedures resulting from
injuries that initially present in an ER. These procedures are
typically referred to and completed by a specialist either
immediately or within a few days following the initial injury.
Axogen’s product portfolio includes Avance®
nerve graft, a biologically active off-the-shelf processed human
nerve allograft for bridging severed peripheral nerves without the
comorbidities associated with a second surgical site; Axoguard
Nerve Connector®, a porcine submucosa ECM coaptation aid for
tensionless repair of severed peripheral nerves; Axoguard Nerve
Protector®, a porcine submucosa ECM product used to wrap and
protect damaged peripheral nerves and reinforce the nerve
reconstruction while preventing soft tissue attachments; Axoguard
HA+ Nerve Protector™, a porcine submucosa ECM base layer coated
with a proprietary hyaluronate-alginate gel, a next-generation
technology designed to enhance nerve gliding and provide short- and
long-term protection for peripheral nerve injuries; and Axoguard
Nerve Cap®, a porcine submucosa ECM product used to protect a
peripheral nerve end and separate the nerve from the surrounding
environment to reduce the development of symptomatic or painful
neuroma. The Axogen portfolio of products is available in the
United States, Canada, Germany, the United Kingdom, Spain, South
Korea, and several other countries.
Cautionary Statements Concerning Forward-Looking
Statements
This press release contains “forward-looking” statements as
defined in the Private Securities Litigation Reform Act of 1995.
These statements are based on management's current expectations or
predictions of future conditions, events, or results based on
various assumptions and management's estimates of trends and
economic factors in the markets in which we are active, as well as
our business plans. Words such as “expects,” “anticipates,”
“intends,” “plans,” “believes,” “seeks,” “estimates,” “projects,”
“forecasts,” “continue,” “may,” “should,” “will,” “goals,” and
variations of such words and similar expressions are intended to
identify such forward-looking statements. Forward-looking
statements include the statement about the upcoming launch of
Avive+ Soft Tissue Matrix, the departure of Angelo Scopelianos in
the first quarter of 2024, and the continuity of the expert team as
we move through the BLA submission process of Avance® Nerve Graft
toward the next commercial phase of our business as a biologic.
Actual results or events could differ materially from those
described in any forward-looking statements as a result of various
factors, including, without limitation, potential disruptions
caused by leadership transitions, global supply chain issues,
record inflation, hospital staffing issues, product development,
product potential, expected clinical enrollment timing and
outcomes, regulatory process and approvals, processing facility
transition timing and expense, financial performance, sales growth,
surgeon and product adoption, market awareness of our products,
data validation, our visibility at and sponsorship of conferences
and educational events, global business disruption caused by
Russia’s invasion of Ukraine and related sanctions, recent
geopolitical conflicts in the Middle East, as well as those risk
factors described under Part I, Item 1A., “Risk Factors,” of our
Annual Report on Form 10-K for the most recently ended fiscal year
and Part II, Item 1A., “Risk Factors,” for our Quarterly Report on
Form 10-Q for the most recently ended fiscal quarter.
Forward-looking statements are not a guarantee of future
performance, and actual results may differ materially from those
projected. The forward-looking statements are representative only
as of the date they are made and, except as required by applicable
law, we assume no responsibility to publicly update or revise any
forward-looking statements.
For more information, visit www.axogeninc.com.
Contact:
Axogen, Inc.
Harold D. Tamayo, VP of Finance and Investor
Relations
htamayo@axogeninc.com
Axogen (NASDAQ:AXGN)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Axogen (NASDAQ:AXGN)
Historical Stock Chart
Von Mai 2023 bis Mai 2024